Huons Meditech wins trademark infringement case against Chinese company
Key Takeaways
- •Huons Meditech said it won a final trademark infringement ruling against Hebei Future Precision Equipments Co. in China.
- •The company said the defendant used the registered trademarks “DermaShine” and “DermaShine Max” on counterfeit products without authorization.
- •Huons Meditech filed the lawsuit on July 1, 2025, and the court ruled in its favor on June 18 before the judgment became final on July 18.
- •The ruling orders the Chinese company to stop infringing activity, destroy counterfeit goods and related materials, and reimburse Huons Meditech’s case costs.
- •Huons Meditech said it plans further legal action against other infringers while continuing to promote authentic products in the Chinese market.
Huons Meditech, a medical device maker under Huons Group, said it has secured a final ruling in a trademark infringement lawsuit against a Chinese company that used its DermaShine trademarks without authorization.
The company said it discovered that Hebei Future Precision Equipments Co. had been manufacturing and selling counterfeit products using the registered trademarks "DermaShine" and "DermaShine Max."
Huons Meditech filed the suit at the Anci District People's Court in Langfang, a city in China's Hebei province, on July 1, 2025, seeking an injunction.
The court ruled in Huons Meditech's favor on June 18, and the judgment became final on July 18 after the one-month appeal period expired.
Under the ruling, the Chinese company must immediately stop all infringing activity and is barred from using trademarks identical or similar to Huons Meditech's registered marks. The court also ordered the destruction of counterfeit products, display stands, packaging and related promotional materials, and required the company to reimburse Huons Meditech's costs in the case within 10 days of the ruling taking effect.
The case underscores how closely medical device makers watch trademark protection in overseas markets, where brand names can be tied directly to product authenticity and customer trust. For Huons Meditech, the ruling provides a legal basis to act against unauthorized use of its marks in China, one of the markets where it said counterfeit DermaShine and Multi Needle products are still circulating beyond the products covered by the judgment. The company said it plans further legal action against other infringers while continuing to promote its authentic products in the Chinese market.
"This legal victory represents meaningful recognition by the Chinese court of the intellectual property rights and brand value unique to DermaShine," Huons Meditech CEO Ha Chang-woo said.
"We will continue to take firm legal action against all unauthorized use of our technologies and brands to protect our intellectual property rights and ensure that customers worldwide can use genuine DermaShine products with confidence."
This article was published with the assistance of generative AI and edited by The Korea Times.